Abstract
Summary
Psilocybin is a classic psychedelic drug that has attracted increasing research interest over the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (TRD) demonstrated encouraging signs of basic safety, further confirmed by a large study in groups of healthy volunteers. The first international multi-centre randomised controlled trial was published in 2022, with signs of efficacy for the 25 mg dose condition in people with TRD when compared with an active placebo. Phase 3 trials in TRD are scheduled to start in 2023. Early evidence suggests that single doses of psilocybin given with psychological support induce rapid improvement in depressive symptoms that endure for some weeks. We therefore provide a timely update to psychiatrists on what psilocybin therapy is, what it is not, and the current state of the evidence-base.
Funder
Research Trainees Coordinating Centre
National Institute for Health and Care Research
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference46 articles.
1. 4 McDaid, D , Park, A-L , Davidson, G , John, A , Knifton, L , McDaid, S , et al. The Economic Case for Investing in the Prevention of Mental Health Conditions in the UK. Mental Health Foundation, 2022.
2. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
3. Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
4. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
5. Drug harms in the UK: a multicriteria decision analysis
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献